Study of Blood Immune Cells in Cancer Patients Compared to Controls

Study Overview
=================
Brief Summary
-----------------
Tumors have a systemic immune modifying effect. They affect the immune system similarly to states of chronic inflammation and these effects can: be monitored through analysis of nk t and myeloid cells mainly through studies of the zeta chain but also through other means may be decreased following effective anticancer therapy - may even be used to study the effectiveness of anticancer therapy are important to monitor if the investigators plan on formulation of systemic immune therapy Thus immumonitoring of systemic blood cells may turn out to be an important prognostic and predictive factor in many cancer types

Detailed Description
-----------------
CD247 Known also as the zeta chain is important for relaying T-cell induced signal transduction. Interestingly studies by Baniash and others have demonstrated that this chain is down regulated in states of chronic inflammation and cancer in peripheral blood T cells and also in NK cells However there has not been a prospective study of this marker in cancer and control patients such a study will reveal not only the levels of CD247 in immune cells of cancer patients compared to controls but may reveal the effect of anticancer therapies on CD247 in cancer patients such a study may contribute significantly to our ability to monitor systemic immune system characteristics in cancer patients and help in any further studies of immunomodulation such as vaccination schemes in such patients

Official Title
-----------------
Observational Immunomonitoring Study of NK/T and Myelocites Status in Cancer Patients and Controls

Conditions
-----------------
Solid Carcinoma

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: patients with cancer or blood donators agreeing to participate in the trial Exclusion Criteria: other disease states which may cause chronic inflammation

Ages Eligible for Study
-----------------
Minimum Age: 16 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| cancer patients<br>as described patietns with solid cancer about to be treated with anticancer therapies | |
| control group<br>normal populations who domated blood for further use | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| changes in immune markers mainly cd247-zeta chain - levels in cancer patients undergoing therapy | Hopefully by this time the investigators will be able to see if there are lower zeta chain intracellular expression levels in cancer patients and whether response to therapy enhances recovery of zeta chain | 4-2013 24 month | 
| levels of zeta chain -cd247 in cancer patients | intracellular levels of cd247 compared to other intracellular proteins and other markers of immune response will be monitored in patients with cancer and a control group in cancer patients the investigators will conduct several tests to analyze effects of therapy | till begining of 2013 ( putative) | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
cancer, immunomonitoring, CD247 -zeta chain, chronic inflamation, anticancertherapy